Policy

SCBGENOME (the Fund) focus on the investment in foreign mutual fund “ARK Genomic Revolution ETF (ARKG)” (Master fund), Actively Managed Exchange Traded Fund (ETF) listed in Chicago Board Options Exchange (Cboe BZX Exchange) and NYSE Arca, United States. The stock exchange in which the Fund will invest is the Chicago Board Options Exchange (Cboe BZX Exchange) in USD. The Master fund managed by ARK Investment Management LLC. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution. Companies within ARKG are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. Under normal circumstances, substantially all of the ARKG’s assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises, ADRs (American Depositary Receipt) and GDRs (Global Depositary Receipt). The Fund will have an average net exposure in investment units of the Master Fund, in an accounting year not less than 80 % of the Fund’s NAV and resulting in having an average net exposure related to foreign country risks in an accounting year not less than 80% of the Fund’s NAV. The Fund may invest in derivatives for a purpose of efficient portfolio management or hedging and may invest in derivatives for hedging foreign exchange, as deemed appropriate to a current situation of investment, which shall be subject to the discretion of fund manager.

Fund Type

ForeignInvestment Funds

Sub Type of Fund

Equity Fund

Registered Fund Capital

3,000 Million Baht

Fund Registration Date

20 Aug 2021

Maturity Date

N/A